Evidence map›Paper›PMID 30636773›Full record

ArticleBritish journal of cancer2019

Circulating tumour cells and their association with bone metastases in patients with neuroendocrine tumours.

Francesca M Rizzo, Clare Vesely, Alexa Childs, Teresa Marafioti, Mohid S Khan, Dalvinder Mandair, Mauro Cives, Leah Ensell, Helen Lowe, Ayse U Akarca and 8 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 35 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Neuroendocrine neoplasia and bone (Review).Experimental and therapeutic medicine · 2021
    Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 2 countries.

Francesca M RizzoDepartment of Oncology, UCL Cancer Institute, University College London, London, UK.
Clare VeselyDepartment of Oncology, UCL Cancer Institute, University College London, London, UK.
Alexa ChildsDepartment of Oncology, UCL Cancer Institute, University College London, London, UK.
Teresa MarafiotiDepartment of Pathology, UCL Cancer Institute, University College London, London, UK.
Mohid S KhanWales Neuroendocrine Tumour Service, Department of Gastroenterology, University Hospital of Wales, Cardiff, UK.
Dalvinder MandairNeuroendocrine Tumour Unit, Department of Gastroenterology, ENETS Centre of Excellence, Royal Free London NHS Foundation Trust, London, UK.
Mauro CivesDepartment of Biomedical Sciences and Human Oncology, University of Bari "A. Moro", Bari, Italy.
Leah EnsellDepartment of Oncology, UCL Cancer Institute, University College London, London, UK.
Helen LoweDepartment of Oncology, UCL Cancer Institute, University College London, London, UK.
Ayse U AkarcaDepartment of Pathology, UCL Cancer Institute, University College London, London, UK.
TuVinh LuongDepartment of Histopathology, Royal Free London NHS Foundation Trust, London, UK.
Martyn CaplinNeuroendocrine Tumour Unit, Department of Gastroenterology, ENETS Centre of Excellence, Royal Free London NHS Foundation Trust, London, UK.
Christos ToumpanakisNeuroendocrine Tumour Unit, Department of Gastroenterology, ENETS Centre of Excellence, Royal Free London NHS Foundation Trust, London, UK.
Daniel KrellNeuroendocrine Tumour Unit, Department of Oncology, ENETS Centre of Excellence, Royal Free London NHS Foundation Trust, London, UK.
Christina ThirlwellDepartment of Oncology, UCL Cancer Institute, University College London, London, UK.
Franco SilvestrisDepartment of Biomedical Sciences and Human Oncology, University of Bari "A. Moro", Bari, Italy.
John A HartleyDepartment of Oncology, UCL Cancer Institute, University College London, London, UK.
Tim MeyerDepartment of Oncology, UCL Cancer Institute, University College London, London, UK. t.meyer@ucl.ac.uk.
University College London · GBRoyal Free London NHS Foundation Trust · GBUniversity of Bari Aldo Moro · ITUniversity Hospital of Wales · GB

Funding

Medical Research Council MR/M009033/1
6 · The paper itself

Abstract

backgroundBone metastases are associated with a worse outcome in patients with neuroendocrine tumours (NETs). Tumour overexpression of C-X-C chemokine receptor 4 (CXCR4) appears predictive of skeletal involvement. We investigated the role of circulating tumour cells (CTCs) and CXCR4 expression on CTCs as potential predictors of skeleton invasion.

methodsBlood from patients with metastatic bronchial, midgut or pancreatic NET (pNET) was analysed by CellSearch. CXCR4 immunohistochemistry was performed on matched formalin-fixed paraffin-embedded (FFPE) samples.

resultsTwo hundred and fifty-four patients were recruited with 121 midgut and 119 pNETs, of which 51 and 36% had detectable CTCs, respectively. Bone metastases were reported in 30% of midgut and 23% of pNET patients and were significantly associated with CTC presence (p = 0.003 and p < 0.0001). In a subgroup of 40 patients, 85% patients with CTCs had CTCs positive for CXCR4 expression. The proportion of CXCR4-positive CTCs in patients with bone metastases was 56% compared to 35% in those without (p = 0.18) it. Staining for CXCR4 on matched FFPE tissue showed a trend towards a correlation with CXCR4 expression on CTCs (p = 0.08).

conclusionsCTC presence is associated with bone metastases in NETs. CXCR4 may be involved in CTC osteotropism and present a therapeutic target to reduce skeletal morbidity.

Indexed as

AdultBiomarkers, TumorBone NeoplasmsFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedNeoplastic Cells, CirculatingNeuroendocrine TumorsParaffin EmbeddingReceptors, CXCR4Biomarkers, TumorCXCR4 protein, humanReceptors, CXCR4

Identifiers

PMID30636773
PMCPMC6353867
OpenAlexW2910870959

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.